I-Mab Announces Participation at Jefferies and Piper Conferences in November

06.11.23 14:00 Uhr Importer

Werte in diesem Artikel

Aktien

1.26 EUR -0.05 EUR -3.82 %

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35^th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

Jefferies London Healthcare Conference (In Person)

Presentation Time	Tuesday, November 14^th at 10:30 a.m. GMT (5:30 a.m. EST)
Presenters	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO
Webcast link	https://wsw.com/webcast/jeff287/imab/1828028 The webcast will also be available under "Event Calendar" on I-Mab's IR website at http://ir.i-mabbiopharma.com/
Meetings	One-on-one and small group meetings: Nov 14 – 16, 2023
Management Participants	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Jefferies representative.

Piper Sandler 35^th Annual Healthcare Conference (In Person)

Presentation Time	Thursday, November 30^th at 8:30 a.m. EST
Presenters	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO
Meetings	One-on-one and small group meetings: Nov 28 – 30, 2023
Management Participants	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Piper Sandler representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, X, formerly known as Twitter, and WeChat.

I-Mab Contacts